FDA Approvals and Innovative Therapies Boost Skin Cancer Diagnosis and Therapeutics Market Growth

Skin cancer diagnosis and therapeutics market was valued at $14,258 million in 2024 and is projected to reach $25,160 million by 2035, growing at a CAGR of 5.3% from 2025 to 2035. This growth is driven by advancements in innovative therapies, including checkpoint inhibitors, cellular therapies, and targeted gene therapies for the treatment of melanoma. For instance, in February 2024, the FDA approved Amtagvi (lifileucel), the first cell therapy for adult patients with unresectable or metastatic melanoma. Melanoma, an ultraviolet light-related skin cancer, is responsible for a major proportion of cancer-related fatalities. Treatment can involve immunotherapy with PD-1 inhibitors and BRAF-targeting drugs. Amtagvi is an autologous tumor-derived T cell immunotherapy consisting of a patient's T cells. The treatment is the first FDA-approved tumor-derived T-cell immunotherapy in melanoma patients with high unmet medical needs.

Browse the full report description of “Skin Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (Melanoma, and Non-Melanoma), by Diagnosis Type (Dermatoscopy, Biopsy, Imaging Techniques, Molecular Diagnostics, and Blood Tests), by Therapeutic Type (Surgical Procedures, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Photodynamic Therapy, Topical Treatments, and Others), and by End User (Hospitals, Specialty Dermatology Clinics, Cancer Treatment Centers, Ambulatory Surgical Centers, Diagnostic Laboratories, and Research & Academic Institutes) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/skin-cancer-diagnosis-and-therapeutics-market

• In December 2024, the US FDA approved Checkpoint Therapeutics' new tab drug for the treatment of skin cancer, based on a trial involving 109 patients, with a response rate of 47% in metastatic and 48% in advanced local stages.

• In March 2022, the FDA approved a new treatment regimen with immunotherapy for metastatic or inoperable melanoma, which is a severe form of skin cancer. Additionally, nivolumab, relatlimab, and checkpoint inhibitor immunotherapy are FDA-approved drugs that treat melanoma and other cancers and target PD-1 and LAG-3 proteins, respectively, to increase immune system activity and cancer destruction.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Cancer Type

o By Diagnosis Type

o By Therapeutic Type

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Sun Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Skin Cancer Diagnosis and Therapeutics Market Report Segment

By Cancer Type

• Melanoma
• Non-Melanoma

By Diagnosis Type

• Dermatoscopy
• Biopsy
• Imaging Techniques
• Molecular Diagnostics
• Blood Tests

By Therapeutic Type

• Surgical Procedures
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Photodynamic Therapy
• Topical Treatments
• Others (Laser Therapy, and Vaccine Therapy )

By End User

• Hospitals
• Specialty Dermatology Clinics
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Research & Academic Institutes

Global Skin Cancer Diagnosis and Therapeutics Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/skin-cancer-diagnosis-and-therapeutics-market